Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CyDerm002
- Development stage
- Preclinical
- Lead developer
- RION
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
CyDerm002 is a preclinical-stage exosome-based drug delivery system developed by RION. It utilizes the company's proprietary PEP™ (Purified Exosome Product) platform, which consists of platelet-derived exosomes. CyDerm002 is specifically engineered to serve as a delivery vehicle for chemotherapeutic agents, leveraging the natural biological properties and uptake mechanisms of exosomes to transport toxic cargo directly to target tissues. By encapsulating chemotherapy drugs within platelet-derived exosomes, the system aims to improve the therapeutic index of cancer treatments by enhancing targeted delivery and potentially reducing systemic off-target toxicities.
Beyond the preview
Go deeper on CyDerm002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CyDerm002.